The long-term safety profile, multiple signals of benefit, and wide application of ivermectin in use against COVID-19 has a massive body of literature to boot. But first, a few words on its history. Ivermectin has been around for 40+ years and between 2000–2007 alone, treated 1.75 billion people worldwide as a result of massive international donation campaigns aimed at treating a parasitic disease colloquially named “river blindness” [1]. What is most noteworthy of this achievement is not the artful international cooperation that engendered it, but the “wonder drug” properties ivermectin possesses. Ivermectin is included in both the WHO’s List of Essential Medicines and List of Essential Medicines for Children - a composite of approved drugs deemed both safe and effective. A study in 2003 detailing the safety, tolerability, and pharmacokinetics of ivermectin specifically in high-dose regimens in healthy adults found that, “Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA-approved dose of 200 ?g/kg” [2]. This FDA-approved 200 ?g/kg (or .2mg/kg) dosing recommendation has long been known and used to treat ivermectin’s on-label administration, and averages to a 12mg dose in a healthy adult weighing 51-65 kg [3].